Search Browse Earnings

Metagenomi Therapeutics, Inc.

Nasdaq:MGX

Biological Products, (No Diagnostic Substances)·EMERYVILLE, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Metagenomi Therapeutics, Inc. — SlamSEC

Revenue

$52.3M

+16.8% YoY

FY 2025

Adj. EBITDA

-$83.5M

-159.7% margin

FY 2025

Net Income

-$78.1M

-149.3% margin

FY 2025

EPS (Diluted)

-$2.36

FY 2025

Stock Price

$1.49

-7.8%

2026-03-06

52W Range

$1.23 – $3.95

P/E Ratio

-0.6x

Market Cap

$55.9M

Cash

$27.4M

FY 2025

Total Debt

—

Net Cash

$27.4M

FY 2025

Enterprise Value

$28.5M

Debt / EBITDA

0.3x

FY 2025

EV / EBITDA

-0.3x

Employees

—